Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News ResMed’s myAir shows benefits for sleep apnoea patients in new study

ResMed’s myAir shows benefits for sleep apnoea patients in new study

13th January 2017

ResMed has highlighted new study data showing the benefits its digital and online support programme myAir can provide for people with sleep apnoea.

New European research from PwC revealed that patients with sleep apnoea who use myAir are generally able to maintain greater adherence to continuous positive airway pressure (CPAP) therapy.

It was shown that myAir patients used their device an average of 46 minutes longer per night compared to other patients, with average CPAP adherence for new myAir patients in their first week of treatment measured at 76 percent, compared to 71 percent for other patients.

The myAir programme enables patients to track their own treatment and get personalised coaching tips to support motivation.

Laurent Morin, ResMed's European senior medical affairs director, said: "myAir's regular reminders, tailored coaching and positive reinforcement offer a valuable additional level of support to the care already provided by sleep clinics."

The PwC study analysed anonymous daily-usage data from more than 23,000 patients in Germany and the UK, of whom more than 1,800 were registered in myAir.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801831085-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.